Seeking Alpha

Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in...

Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in senior secured discount notes to be used in part to develop Phase 3 clinical trials of its AFREZZA product. The move follows up last month's FDA clearance on late-stage trials for the inhaled insulin therapy.
Comments (1)
  • Hooray! Money to see them through resubmission.
    23 Sep 2011, 03:28 PM Reply Like
DJIA (DIA) S&P 500 (SPY)